-
Overcoming challenges of HERG potassium channel liability through rational design [Elektronski vir] : Eag1 inhibitors for cancer treatmentToplak, Žan ...Two decades of research have proven the relevance of ion channel expression for tumor progression in virtually every indication, and it has become clear that inhibition of specific ion channels will ... eventually become part of the oncology therapeutic arsenal. However, ion channels play relevant roles in all aspects of physiology, and specificity for the tumor tissue remains a challenge to avoid undesired effects. Eag1 (KV10.1) is a voltage-gated potassium channel whose expression is very restricted in healthy tissues outside of the brain, while it is overexpressed in 70% of human tumors. Inhibition of Eag1 reduces tumor growth, but the search for potent inhibitors for tumor therapy suffers from the structural similarities with the cardiac HERG channel, a major off-target. Existing inhibitors show low specificity between the two channels, and screenings for Eag1 binders are prone to enrichment in compounds that also bind HERG. Rational drug design requires knowledge of the structure of the target and the understanding of structure-function relationships. Recent studies have shown subtle structural differences between Eag1 and HERG channels with profound functional impact. Thus, although both targets' structure is likely too similar to identify leads that exclusively bind to one of the channels, the structural information combined with the new knowledge of the functional relevance of particular residues or areas suggests the possibility of selective targeting of Eag1 in cancer therapies. Further development of selective Eag1 inhibitors can lead to first-in-class compounds for the treatment of different cancers.Source: Medicinal research reviews. - ISSN 1098-1128 (42, iss. 1, 2022, str. 283.226)Type of material - e-articlePublish date - 2021Language - englishCOBISS.SI-ID - 62365443
Author
Toplak, Žan |
Hendrickx, Louise Antonia |
Abdelaziz, Reham |
Shi, Xiaoyi |
Peigneur, Steve |
Tomašič, Tihomir |
Tytgat, Jan |
Peterlin-Mašič, Lucija |
Pardo A., Luis
Topics
Farmacevtska kemija |
Kalij |
Rak (medicina) |
arrhythmia |
cancer |
Eag1 |
potassium channels |
HERG |
rational drug design |
Eag1 inhibitorji |
zdravljenje raka |
kalijevi kanali
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|---|
Toplak, Žan | 52375 |
Hendrickx, Louise Antonia | |
Abdelaziz, Reham | |
Shi, Xiaoyi | |
Peigneur, Steve | |
Tomašič, Tihomir | 28334 |
Tytgat, Jan | |
Peterlin-Mašič, Lucija | 19317 |
Pardo A., Luis |
Select pickup location:
Material pickup by post
Notification
Subject headings in COBISS General List of Subject Headings
Select pickup location
Pickup location | Material status | Reservation |
---|
Please wait a moment.